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Abstract
Introduction: GP88 (progranulin) has been implicated in tumorigenesis and resistance to anti-estrogen therapies
for estrogen receptor positive (ER+) breast cancer. Previous pathological studies showed that GP88 is expressed in
invasive ductal carcinoma (IDC), but not in normal mammary epithelial tissue, benign lesions or lobular carcinoma.
Based on these results, the present study examines GP88 prognostic significance in association with recurrence and
death risks for ER+ IDC patients.
Methods: Two retrospective multi-site clinical studies examined GP88 expression by immunohistochemistry (IHC)
analysis of paraffin-embedded breast tumor tissue sections from ER+ IDC patients (lymph node positive and
negative, stage 1 to 3) in correlation with patients’ survival outcomes. The training study established a GP88 cut-off
value associated with decreased disease-free (DFS) and overall (OS) survivals. The validation study verified the GP88
cut-off value and compared GP88 prognostic information with other prognostic factors, particularly tumor size,
grade, disease stage and lymph node status in multivariate analysis.
Results: GP88 expression is associated with a statistically significant increase in recurrence risk for ER+ IDC patients.
The training study established that GP88 3+ score was associated with decreased DFS (P = 0.0004) and OS (P =
0.0036). The independent validation study verified that GP88 3+ score was associated with a 5.9-fold higher hazard
of disease recurrence and a 2.5-fold higher mortality hazard compared to patients with tumor GP88 < 3+. GP88
remained an independent risk predictor after considering age, ethnicity, nodal status, tumor size, tumor grade,
disease stage, progesterone receptor expression and treatments.
Conclusions: The survival factor GP88 is a novel prognostic biomarker, predictive of recurrence risk and increased
mortality for non-metastatic ER+ IDC patients. Of importance, our data show that GP88 continues to be a
prognostic factor even after five years. These results also provide evidence that GP88 provides prognostic
information independent of tumor and clinical characteristics and would support prospective study to examine
whether GP88 expression could help stratify patients with ER+ tumors for adjuvant therapy.
Introduction
GP88, also called progranulin, PC-cell derived growth
factor or acrogranin is an 88-kDa glycoprotein identified
by a biological screen for protein targets associated with
high tumorigenicity [1,2]. GP88 is the largest member of
a unique family of double cysteine-rich polypeptides
containing seven and a half granulins/epithelins 6 kDa
repeats [1-3]. Our laboratory was the first to demon-
strate the biological activity of the 88 kDa GP88 precur-
sor as an autocrine growth/survival factor for human
breast cancer cells. GP88 stimulates important tumori-
genesis steps, including proliferation, estrogen-indepen-
dence, survival, migration, invasion and angiogenesis
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[1,2]. Others have identified GP88 by microarray analy-
sis as being upregulated in doxorubicin-resistant breast
cancer cells whereas GP88 exogenous administration
conferred resistance to the killing effect of doxorubicin
[4]. Moreover, progranulin was selected as an upregu-
lated secreted protein by screening for the most fre-
quently upregulated genes in breast cancer [5]. Several
laboratories have also shown that GP88 plays a role in
tumorigenesis, angiogenesis and wound healing in other
cancer types and cellular models [6-12]. The pathways
involved in GP88 signaling include the mitogen-acti-
vated protein kinase (ERK 1/2), phosphatidylinositol 3-
kinase and focal adhesion kinase, leading to the activa-
tion of cell cycle regulatory proteins, such as cyclin D1,
cyclin B and CDK4 [13,14]. GP88 also abrogates the
requirement for the insulin-like growth factor receptor
[15].
Screening of GP88 expression in human breast cancer
cell lines indicated that GP88 was highly expressed in
both ER+ and ER- human breast carcinomas, whereas it
was undetectable in non-tumorigenic mammary epithe-
lial cells. Inhibition of GP88 expression by transfection
of GP88 antisense cDNA in ER- MDA-MB-468 cells
resulted in a dramatic reduction of tumor incidence and
tumor size in nude mice [16]. In ER+ cells, GP88
expression was stimulated by 17-b estradiol [17]. GP88
was also found to mediate estrogen mitogenic activity;
moreover inhibition of GP88 action by neutralizing anti-
bodies blocked the ability of estrogen to stimulate
Cyclin D1 [17]. Acquisition of resistance to the anti-
estrogen tamoxifen, both in vitro and in vivo was corre-
lated to overexpression of GP88 in MCF-7 breast cancer
cells [18,19]. In addition, GP88 has been associated with
letrozole resistance in aromatase overexpressing cells
and found to be overexpressed in the naturally letrozole
resistant cells LTLT and Ac1-letR [20]. In HER-2 over-
expressing breast cancer cells, GP88 cross-talked with
HER-2 and stimulate HER-2 phosphorylation leading to
Trastuzumab resistance [21]. Pathological studies with
203 formalin-fixed paraffin-embedded human breast
cancer tissue biopsies indicated that GP88 was preferen-
tially expressed in ductal carcinoma with little expres-
sion in lobular carcinoma, while benign lesions and
normal mammary epithelial tissues were negative [22].
Similar results have been observed by others [23]. In
ductal carcinoma in situ (DCIS), high GP88 expression
positively correlated with high nuclear grade [22]. In
invasive ductal carcinoma (IDC), high GP88 expression
positively correlated with tumor grade and with the
expression of clinical parameters of poor prognosis,
such as ER, p53 and the proliferation index Ki67 [22].
Interestingly, GP88 expression was not correlated to
HER-2 expression, indicating that GP88 and HER-2
were independent biomarkers [22]. These various
biological and pathological studies pointed out the
importance of GP88 in the pathogenesis of breast cancer
and suggested that GP88 breast tissue expression could
have prognostic value. Since GP88 mediated estrogen-
independence and conferred anti-estrogen therapy resis-
tance to ER+ breast cancer, we focused this investigation
on ER+ breast tumors in order to determine whether
GP88 expression is a prognostic factor in ER+ non
metastatic IDC. Two independent retrospective training
and validation studies were carried out to examine the
association of GP88 breast tissue expression with survi-
val outcomes in patients with ER+ IDC.
Materials and methods
Study populations
Two retrospective breast cancer patient cohorts were
used, one for the training study and the other one for
the validation phase. The sample size was calculated
using SAS PROC POWER (SAS Institute Inc., Cary, NC,
USA). Based on our previous studies [22], input assump-
tions were that the high-risk group would comprise 14%
of the patients and have a five-year survival of 60%,
while the low-risk group’s five-year survival would be
85%. Sample attrition due to censoring was set at 1%
per month. The target of 80% power was then given by
sample sizes of 266 assuming that patients’ clinical sta-
tus was typically known for five years following initial
diagnosis, and 217 assuming clinical status was typically
known for seven years following initial diagnosis.
The training study examined cases from 267 patients
diagnosed between 1985 and 2001 with ER+ invasive
ductal carcinoma (IDC) from five sites: Fox Chase Can-
cer Center (FCCC) (Philadelphia, PA, USA), Kaiser Per-
manente, (Portland, OR, USA), Kaiser Permanente
(Miami, FL, USA), Washington University, (St. Louis,
MO, USA) and University of Miami, (Miami, FL, USA).
The last four sites were part of the Cooperative Breast
Cancer Tissue Resources (CBCTR) from the National
Cancer Institute [24].
For the independent validation study, tumor sections
from 295 patients with ER+ IDC diagnosed between
1995 and 2003 were obtained from FCCC and from the
EEH Breast Cancer Research and Treatment Center
(Baton Rouge, LA, USA). Upon histological examination,
31 of the 295 cases contained slides with no evaluable
tumor tissue and were excluded from the analysis.
Therefore, the final database for analysis included 264
cases.
For this study, retrospective patients’ information and
material were de-identified and given new unique case
numbers prior to shipment. The study was reviewed and
approved by the Chesapeake Research Review’s IRB
(CRRI 1006001). The board confirmed that informed
consent was not required for this study.
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Clinical and pathological parameters provided by the
tissue repositories included age at diagnosis, disease
stage, tumor size, tumor grade, steroid receptor status
(estrogen and progesterone receptors), lymph node sta-
tus, adjuvant treatment (chemotherapy, hormone ther-
apy) and clinical outcomes, such as recurrence and
survival information. All patients underwent surgery and
none of the patients received neo-adjuvant therapy.
Since the menopausal status of patients was not pro-
vided in the database, age was used as a surrogate with
patients aged > 50 years old considered to be post-
menopausal for this analysis. Estrogen receptor status
and progesterone receptor status for the cases examined
had been determined by IHC using Ventana IHC kits
(Ventana, Tucson, AZ, USA). All cases examined were
ER+.
GP88 expression by Immunohistochemistry
GP88 expression was measured by immunohistochemis-
try. Antibody, deparaffinization, antigen retrieval, and
GP88 staining and scoring had been previously validated
and described [22]. Briefly, formalin-fixed paraffin-
embedded (FFPE) blocks from patients that fit the inclu-
sion criteria were retrieved. Tissue sections of 5 μm
were freshly placed onto coated plus microscope glass
slides (Surgipath, Richmond, IL, USA). Sections were
deparaffinized with xylene and rehydrated through a
graded ethanol series [22]. Antigen retrieval was con-
ducted for 25 minutes in 0.2 M citrate buffer pH 6.0 in
a 94°C water bath. GP88 was detected in tissue sections
using the Oncostain 88™ immunohistochemistry kit
(A&G Pharmaceutical, Columbia, MD, USA) consisting
of incubation with an anti-human GP88 mouse mono-
clonal antibody (clone 6B3) developed in our laboratory
using recombinant human GP88 as antigen, followed by
washing, and incubation with HRP-conjugated second-
ary goat anti-mouse antibody (Dako, Carpinteria, CA,
USA). Bound antibody was detected using DAB as chro-
mogen (Dako). Slides were then washed and counter-
stained with Mayer’s Hematoxylin. Slides for both train-
ing and validation studies were stained in a blinded
fashion by an independent CLIA laboratory (LabCorp,
Research Triangle Park, NC, USA) using a Dako auto-
stainer. In addition, 100 duplicate slides from the train-
ing study were stained in parallel using a Ventana
Benchmark XT ™ autostainer (Ventana) to demonstrate
that staining was not platform dependent. In all cases,
GP88 negative and positive breast cancer control slides
provided with the kit were included in each IHC stain-
ing set as internal controls for all the runs.
Evaluation of immunohistochemistry results
GP88 immunoreactivity was cytoplasmic and granular,
and scoring was semi-quantitatively categorized as: <
10% of cells staining: negative (0); > 10% of cells stain-
ing: positive with positive staining graded from weak/
focal (1+) to moderate/focal or diffuse (2+) to strong/
diffuse (3+) as described previously [22]. The immunos-
tained slides were evaluated by two board certified
pathologists at two separate institutions who indepen-
dently examined the entire tissue section while blinded
to the clinical data. Reading agreement was found to be
96% concordant between the two pathologists. Non-con-
cordant cases were resolved by a third pathologist
blindly scoring these cases and using the two out of
three rule for final scoring determination.
Statistical analysis
Analysis was done following the REporting recommen-
dations for tumor MARKer prognostic studies
(REMARK) guidelines [25]. Descriptive statistics were
used to summarize patient characteristics.
The statistical analysis of the results was based on
evaluating the GP88 test performance for its ability to
predict recurrence using Kaplan-Meier curves and the
Cox proportional hazard (CPH) models for quantifica-
tion of risk.
The correlation between GP88 scoring, clinico-patho-
logic characteristics and survival outcomes was deter-
mined using Pearson’s Χ2 test. Disease-free survival
(DFS) was defined as the time interval from date of
diagnosis to first recurrence (local or distant). Overall
survival (OS) was defined as the time interval from date
of diagnosis to time of last follow-up or death. Time to
recurrence (local, regional and distant) was censored at
the time of last disease-free follow-up, and at death for
those patients who died without a previous recurrence.
Survival curves for DFS and OS were derived from
Kaplan-Meier estimates and the curves were compared
using the log rank tests. A CPH model was applied to
quantify the hazard associated with GP88 scores. All sta-
tistical tests were two-sided and P-values less than 0.05
were considered as statistically significant. The statistical
analyses were performed using SAS V9.2 (SAS Institute,
Cary, NC, USA). Additional potential correlations
between GP88 expression and prognosis were carried
out using analysis of deviance of a sequence of CPH
models as described in the results section.
Multivariate analysis examined whether the informa-
tion provided by GP88 expression duplicated or was
additive to that provided by conventional risk factors,
such as age, ethnicity, progesterone receptor (PR)
expression, tumor size, tumor grade, disease stage,
lymph node status and treatments. This was performed
with CPH models using each of the risk factors alone,
or along with GP88. Analysis of deviance between these
pairs of model fits provided formal tests of the addi-
tional information in GP88. The hazard ratio for GP88
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in these models quantified the impact of GP88 adjusted
for each of the conventional risk indicators in turn. A
comprehensive CPH model including all significant cov-
ariates along with GP88 was also performed to deter-
mine whether GP88 remained highly significant even
when adjusted for other risk factors simultaneously.
Results
Establishment of GP88 cut-off value for prediction of risk
of recurrence
A retrospective multi-institution training study using
267 ER+ breast cancer cases (see Methods section) was
carried out to examine GP88 IHC scores and determine
a GP88 cut-off score for defining high and low GP88
expression groups.
Patients’ and tumors’ characteristics of the training
group were the following: The median age of the
patients in the training study was 63 with a range of 28
to 88; stage distribution was 57% for stage 1, 33% for
stage 2, 4% for stage 3 and 4% stage unknown; tumor
size distribution was 63% for size ≤ 2 cm and 83% of
patients were lymph node negative. Median follow-up
was 125 months.
GP88 expression in tumor tissues was determined by
IHC staining and scored as 0, 1+, 2+ and 3+ by the cer-
tified pathologists as described in the method section.
Figure 1 provides photomicrograph examples of the dif-
ferent GP88 scores.
To evaluate GP88 prognostic significance, analysis of
GP88 expression in relation to DFS and OS was then
carried out using Kaplan-Meier estimation and log-rank
testing. In particular, Kaplan-Meier survival curves eval-
uated the prognostic significance of every GP88 score
(0, 1+, 2+, and 3+) for DFS (Figure 2A) and OS (Figure
2B). There was no significant difference in DFS or OS
between patients with GP88 scores of 0, 1+ and 2+. In
contrast, there was a markedly significant decrease in
DFS and OS for patients whose tumors had a high
GP88 expression with a GP88 score of 3+ (P = 0.00004
for DFS and P = 0.0036 for OS). These results pointed
to the existence of a GP88 threshold effect with GP88 3
+ score showing markedly higher recurrence and death
rates than lower GP88 levels (0, 1+ and 2+).
The association between GP88 expression level and
survival was confirmed by formal logrank tests shown in
Table 1.
Validation of the GP88 cut-off value
We next sought to validate the results from the training
study using an independent multi-site retrospective
cohort of 264 ER+ IDC cases. The specific objectives of
this validation study were to not only verify the GP88
cut-off value, but also quantify GP88 performance, and
test whether the information in GP88 duplicates or is
additive to that found in covariates, such as age, PR
expression, tumor size, tumor grade, lymph node status,
disease stage and treatments. None of the cases used in
the cut-off training study was included in the cut-off
validation study. Descriptive statistics for patient and
tumor characteristics are described in Table 2. Median
follow-up was 91.3 months.
The cases included in the validation study presented
similar patient demographics (age and ethnicity) and
tumor characteristics (PR expression, tumor size and
grade) as the training study. The validation study had a
higher percentage of lymph node positive cases (58.7%),
whereas the training cohort was mostly lymph node
negative (83%). Based on the cut-off established by the
training study, GP88 scores were grouped as 3+ and < 3
+ (by combining scores 0, 1+ and 2+) for this analysis.
In the GP88 = 3+ validation group representing 18%
(47 cases) of all 264 cases examined, 47% had a recur-
rence and 53% died. In the GP88 < 3+ group represent-
ing 82% (217 cases) of all cases examined, 11% had a
recurrence and 29% died. Table 3 provides the distribu-
tion of patients at risk of recurrence and of death for
the two GP88 groups (< 3+ and 3+).
The first step in analysis of the validation study was to
establish the DFS curves for the cases with high GP88
(GP88 = 3+) and low GP88 (GP88 < 3+) expression.
Figure 3A shows the Kaplan-Meier DFS function for the
cut-off establishment training study that had been re-
plotted by grouping the GP88 scores of 0, 1+ and 2+ as
Gp88 < 3+, whereas Figure 3B shows the corresponding
Kaplan-Meier graph for the validation data. The results
of the validation study verified the GP88 threshold
score. Examining the Kaplan Meier curves for DFS func-
tion shows that the large separation between low and
high GP88 groups seen in the training study is con-
firmed and, in fact, strengthened, by the validation data.
Figure 3C shows the OS function from the cut-off-
establishment training study and Figure 3D is the curve
from the validation study for the GP88 scoring grouped
as GP88 < 3+ and GP88 = 3+. Comparing the two fig-
ures also shows the agreement between the results
obtained in the training and validation studies.
The formal log-rank tests confirm the high statistical
significance of the separation between the two GP88
groups (GP88 = 3+ and GP88 < 3+) in the validation
study. The chi-squared and P-values for DFS are 43.79
and < 0.0001, respectively. The chi-squared and P-values
for OS are 14.89 and 0.0001, respectively.
These results from the validation study confirm the
high significance of the association between high GP88
expression in breast tumor tissues and poor clinical
outcomes.
Based on the KM survival graphs, the low GP88 group
had good survival probabilities with 5-year and 10-year
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DFS probabilities of 91% and 86% and 5-year and 10-
year OS probabilities of 85% and 60%, respectively. In
comparison, the high GP88 group showed a dramatic
decrease in survival probabilities with 5-year and 10-
year DFS probabilities of 62% and 29% along with 5-
year and 10-year OS probabilities of 64% and 33%,
respectively.
Of interest, Kaplan Meier curves for DFS function
show that the separation between high and low risk
GP88 groups was also observed when cases were segre-
gated into lymph node negative and lymph node positive
groups (Figures 3E, F).
Univariate and multivariate analysis
Cox proportional hazard (CPH) regression was also per-
formed to determine the association between GP88 tis-
sue expression and survival outcomes (DFS and OS).
Table 4 provides the coefficients of elevated GP88 with
Wald P-value and hazard ratios (HR) and shows that
high GP88 is associated with an HR of 5.93 for DFS and
2.45 for OS. Univariate analysis shows that other predic-
tors of survival were tumor size, tumor grade, age, dis-
ease stage, lymph node status and treatment for DFS
(Table 5) and/or OS (Table 6). A major question is
whether the information from GP88 expression dupli-
cates, or is independent of, that contained in the other
conventional risk factors. These questions were explored
with sequences of CPH models (Tables 5, 6, 7). Indica-
tor variables were set up for each covariate, and a
sequence of CPH models fitted. The first used just the
covariate; then the GP88 indicator was added; and
finally the interaction between the covariate and the
indicator was added. The resulting analysis of deviance
gave rise to tests of interaction between the covariate
and GP88, and the coefficient of GP88 in the model
using it along with the covariate which quantifies the
Figure 1 Immunohistochemical staining for GP88 expression in paraffin- embedded invasive ductal carcinoma tissue sections.
Representative photomicrographs of breast cancer tissue sections from ER+ IDC showing various GP88 expression 0, 1+, 2+, and 3+, respectively
are provided.
Serrero et al. Breast Cancer Research 2012, 14:R26
http://breast-cancer-research.com/content/14/1/R26
Page 5 of 12
relationship between survival and GP88 corrected for
the covariate. The results of Table 5 show that there
was a marginally significant interaction of GP88 with
tumor size in DFS, but no hint of interaction between
GP88 and any of the other indicators investigated, such
as tumor grade, lymph node status, disease stage, PR
expression, age, ethnicity and treatments. Similar obser-
vations were obtained for OS in Table 6. This indicates
Figure 2 Kaplan-Meier estimates for disease-free survival and overall survival by GP88 scores in the training study. GP88 expression for
the 267 ER+ IDC cases was examined by IHC and reported as GP88 scores of 0, 1+, 2+ and 3+. Kaplan-Meier estimates for DFS (A) and OS (B)
were determined for each GP88 score group. The difference between the curves was estimated by the log-rank test.
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that the information on DFS and OS provided by GP88
is additive to that contributed by other indicators. The
data point out that GP88 remains highly significant even
after adjustment for each of these covariates. Having
GP88 = 3+ corresponds to a hazard ratio for recurrence
between 4.8 and 6.2, after correction for the covariates
(Table 5). Elevated GP88 corresponds to a hazard ratio
between 2.0 and 2.7 for decrease in OS (Table 6). A
final pair of multivariate analyses incorporating GP88,
age, ethnicity, tumor size, tumor grade and disease stage
(Table 7) further demonstrated that GP88 remained an independent prognostic indicator for both DFS and OS
as shown by the fact that HR for GP88 adjusted for all
the other indicators remained unaffected and significant
(HR = 5.15 with P < 0.0001 for DFS and HR = 1.8 with
P = 0.0148 for OS).
Discussion
We have demonstrated previously that GP88 plays a role
in the pathogenesis of breast cancer. Increased GP88
expression in human breast adenocarcinoma cell lines
was associated with increased tumorigenicity, whereas
inhibition of GP88 expression by antisense led to a 90%
reduction in tumor growth and tumor incidence in
mouse xenograft studies [15]. A neutralizing anti-human
GP88 antibody was shown to have efficacy in pre-clini-
cal studies, including mouse xenografts. In ER+ breast
cancer cells, GP88 acts downstream of estrogen and can
substitute for estrogen to stimulate proliferation [17,18].
Moreover, high GP88 allows cells to become tamoxifen
resistant while remaining ER+. Pathological studies
showed that GP88 expression was negative in normal
mammary epithelial tissue, benign lesions and lobular
carcinoma. In contrast, 60% of DCIS and 80% of IDC
stained positive for GP88 (ranging from 1+ to 3+) [22].
In IDC, GP88 expression correlated with proliferation
index Ki67 expression, p53 expression but was indepen-
dent of HER-2 expression [22]. Here, we investigated
whether GP88 expression was prognostic for ER+ IDC.
For this purpose, we have developed an IHC test vali-
dated to consistently and reproducibly measure GP88
levels in FFPE tissue sections using several automated
and manual staining platforms [22]. In the present
study, this assay was then utilized to examine GP88
expression in two independent studies totaling 531 cases
and to correlate GP88 IHC levels with DFS and OS. We
Table 1 Logrank testing for GP88 score cut-off
establishment in the training trial
GP88 scores DFS OS
Between Chi-squared P Chi-squared P
1 and 0 1.35 0.2459 2.06 0.1512
2 and 0, 1 0.21 0.6430 0.01 0.9159
3 and 0, 1, 2 17.07 0.00004 8.46 0.0036
Table 2 Patients characteristics for the validation study
Characteristics Groups Number %
Age at diagnostics Median 59.3
Range 24.4 to 92.8
Age distribution < 50 65 24.6
> 50 199 75.4
Ethnicity Caucasian 228 86.4
African-American 31 11.7
Asian 5 1.9
PR Positive 176 66.6
Negative 65 24.6
Unknown 23 8.7
Tumor Size ≤ 2 cm 173 65.5
2 to 5 cm 73 27.7
> 5 cm 18 6.8
Tumor grade Grade 1 8 3.2
Grade 2 94 37.6
Grade 3 148 59.2
Unknown 14 5
Stage 1 72 27.4
2 154 58.6
3 35 13.3
Lymph Node Negative 109 41.3
Positive 155 58.7
Hormone No 75 28.4
Yes 189 71.6
Chemotherapy No 128 48.5
Yes 136 51.5
Radiation No 219 83
Yes 45 17
GP88 < 3+ 217 82
= 3+ 47 18
Table 3 Patients at risk for recurrence or death at
successive follow-up times
Patients at risk for recurrence
years 0 1 2 3 4 5 6 7 8 9 10 11 12
GP88 <
3+
217 213 199 187 170 142 111 88 62 38 29 21 11
GP88 =
3+
47 44 41 33 25 19 12 8 4 2 1 0 0
Patients at risk for death
years 0 1 2 3 4 5 6 7 8 9 10 11 12
GP88 <
3+
217 214 201 192 178 148 120 9 66 42 30 22 11
GP88 =
3+
47 46 44 37 31 25 18 13 6 2 1 0 0
The data show the number of patients at risk for recurrence or death at 12-
month intervals out to 12 years following initial diagnosis in the two GP88
groups (GP88 < 3+ and GP88+3+) in the validation study. The maximum
follow-up was 122 months in the GP88 = 3+ group and 205 months in the
GP88 < 3+ group,
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report here that a high GP88 expression of 3+ repre-
sents a threshold that can stratify ER+ breast cancer
patients in a high risk group associated with an
increased probability of recurrence and mortality when
compared to patients with a lower GP88 expression
(GP88 < 3+). These findings established in the training
study were replicated in the independent validation
study for both lymph node negative and positive
Figure 3 Kaplan-Meier estimates for disease-free survival and overall survival by GP88 scores in the validation study. GP88 scores for cases
examined were grouped as GP88 < 3+ and GP88 = 3+. Kaplan-Meier survival estimates for DFS and OS were established for the two GP88 groups. A:
DFS in high (GP88 = 3+) and lower GP88 score (GP88 < 3+) groups in the training study. B: DFS in high and low GP88 score groups in the validation
study. C: OS in high and low GP88 score groups in the training study. D: OS in high and low GP88 score groups in the validation study. E-F: Kaplan-
Meier survival estimates for DFS were established for the two GP88 groups in the validation study separated by lymph node status. E: DFS for high and
low GP88 groups of lymph node negative cases. F: DFS for high and low GP88 scores of lymph node positive cases.
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patients. Analysis of deviance to examine the association
of GP88 with each clinical indicator showed that GP88
was independent of patients’ demographics, such as age
and ethnicity, of tumor characteristics, such as tumor
size, tumor grade, PR status, disease stage and lymph
node status, and of treatments. Interestingly, additional
multivariate analysis further demonstrated that GP88
expression maintained its prognostic value even when
adjusted to combined indicators, such as age, ethnicity
and tumor characteristics simultaneously. Survival analy-
sis indicates that patients whose tumor stained 3+ for
GP88 had an HR of 5.9-fold corresponding to a dra-
matic increase in probability of recurrence compared
with patients whose tumors had no or low GP88 expres-
sion. In multivariate analysis, adjusted HR for high GP88
remained 5.2-fold, thereby supporting the clinical utility
of GP88 tumor tissue determination as an independent
prognostic indicator of survival. Of note, analysis of KM
graphs (Figure 3) supported by tests of fit of the CPH
model (data not shown) indicates that GP88 retains its
prognostic value over the whole range of survival times
observed. This would suggest that GP88 can be
proposed as a prognostic indicator beyond five years for
ER+ breast cancer patients.
The prognostic value of GP88 tissue expression is not
limited to breast cancer. Studies from other laboratories
have shown that GP88 (progranulin expression) was
found to be prognostic for ovarian cancer [26].
There have been several biomarkers described to be
prognostic in breast cancer, particularly in ER+ node
negative early stage breast cancer patients [27], either by
measuring protein or RNA expression. Tumor expres-
sion of the proliferation antigen Ki67 is used to assess
the prognosis of cancer patients [28]. In addition,
recently, prognostic value of Ki67 expression was
demonstrated after short-term pre-surgical endocrine
therapy for primary breast cancer [29]. It is interesting
to note that GP88 is a growth factor shown to upregu-
late proliferation markers, such as pCNA (Kim and Ser-
rero, unpublished results) and to correlate with Ki67
expression [22]. It would be interesting to determine
whether GP88 has prognostic value in association with
Ki67 in these conditions.
Recently, several of the prognostic indicator tests have
required the use of RNA to measure multi-gene expres-
sion. In particular, Oncotype DX (Genomic Health, Red-
wood City, CA, USA) provides a recurrence score based
on the expression of 21-genes [30]. Mammaprint (Agen-
dia, Irvine, CA, USA) determine the expression of 70
genes [31]. More recently, the expression index of the
two genes HoxB13:IL17BR was demonstrated to be
prognostic in early stage lymph node negative breast
cancer patients [32]. Our data support further investiga-
tion of GP88 IHC expression in breast cancer tissue
Table 4 CPH coefficient and hazard ratio for GP88 3+ for
DFS and OS in the validation study
Variable DF Estimate SE P-value HR 95% CI
DFS 1 1.78 0.30 < 0.0001 5.93 3.29 to 10.68
OS 1 0.90 0.24 0.0002 2.45 1.54 to 3.94
The successive columns show the coefficient of elevated GP88 in the CPH
model along with its standard error and Wald P-value. The final columns
provide the hazard ratio (HR) of elevated GP88 with 95% confidence interval
(95% CI).
Table 5 Impact of GP88 and other clinical risk factors on diease-free survival.
Covariate Univariate GP88 adjusted for covariate
HR CI P-value P-value HR CI Interaction P-value
GP88 (3+ vs. < 3+) 5.93 3.23 to 10.7 < 0.0001 < 0.0001 5.93 3.29 to 10.68 -
Ethnicity (Caucasian vs. non-Caucasian) 2.32 1.17 to 4.58 0.0251 < 0.0001 5.90 3.26 to 10.67 0.09
Tumor size (> 2 cm vs. ≤ 2 cm) 1.85 1.23 to 2.78 0.0052 < 0.0001 5.41 2.97 to 9.87 0.03
Tumor size (> 5 cm vs. ≤ 5 cm) 3.09 1.37 to 6.96 0.0167
Grade (> 1 vs. ≤ 1) 1.68 0.23 to 12.2 0.5757 < 0.0001 5.86 3.18 to 10.78 0.25
Grade (> 2 vs. ≤ 2) 1.36 0.74 to 2.51 0.3124
Stage (> 1 vs. ≤ 1) 2.56 1.14 to 5.75 0.0116 < 0.0001 4.85 2.66 to 8.87 0.89
Stage (> 2 vs. ≤ 2) 4.67 2.48 to 8.77 < 0.0001
Nodal status (Pos. vs. Neg.) 2.12 1.11 to 4.05 0.0177 < 0.0001 5.60 3.09 to 10.14 0.40
Age (> 50 yrs vs. ≤ 50 yrs) 0.73 0.40 to 1.34 0.3179 < 0.0001 5.96 3.30 to 10.74 0.83
PR (Pos. vs. Neg.) 1.04 0.52 to 2.08 0.9029 < 0.0001 6.53 3.52 to 12.10 0.49
Adjuvant endocrine therapy (Pos. vs. Neg.) 1.66 0.80 to 3.45 0.1542 < 0.0001 5.89 3.27 to 10.62 0.58
Adjuvant chemotherapy (Pos vs. Neg.) 4.33 2.08 to 9.04 < 0.0001 < 0.0001 4.78 2.63 to 8.70 0.52
Adjuvant radiotherapy (Pos. vs. Neg.) 10.20 5.54 to 19.1 < 0.0001 0.0002 3.29 1.75 to 6.19 0.09
CPH analysis was used to examine the impact of GP88 score and other individual clinical risk factors on DFS.
CI, 95% confidence interval; HR, hazard ratio; PR, progesterone receptor. In adjusted analysis, the successive columns provide the HR of elevated GP88 adjusted
for each indicator with its P-value and 95% CI and the P-value of the analysis of deviance test statistics for interaction between GP88 and that indicator.
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sections as a protein-based prognostic test and risk stra-
tifier for ER+ breast cancer patients for lymph node
positive as well as lymph node negative patients. This
antibody-based test that detects the presence of the
GP88 protein in tissues would present the advantage of
being used alongside determination of other protein-
based biomarkers already assayed in the pathology set-
ting and used as a prognostic indicator. Moreover, an
additional interesting characteristic is that GP88 is a
secreted protein and is measurable in the blood of
healthy individuals and women with invasive breast can-
cer. It is, in fact, possible to measure the level of circu-
lating GP88 in addition to tissue GP88 determination in
breast cancer patients. Our preliminary results have
shown that GP88 levels are elevated in sera of breast
cancer patients when compared to healthy individuals
[33].
Additional clinical studies where patients’ tissue and
serum samples are simultaneously collected will allow
examining this possibility in detail. The availability of
both tests and the demonstration that they can detect
GP88 in biological samples should encourage further
investigation of GP88 prognostic value of tissue and
serum GP88.
In particular, since GP88 expression has been asso-
ciated with drug resistance in models of tamoxifen and
aromatase inhibitor resistance, one key question would
be to examine whether GP88 expression can stratify
patients in relation to treatment response in the adju-
vant settings. Availability of biological samples from well
controlled prospective studies should allow investigating
this possibility. In addition, expression of HER-2 and
Ki67 biomarkers should be considered in future studies
of GP88 tissue expression as our retrospective cases did
Table 6 Impact of GP88 and other clinical risk factors on overall survival.
Covariate Univariate GP88 adjusted for each covariate
HR CI P-value P-value HR CI Interaction P-value
GP88 (3+ vs. < 3+) 2.45 1.53 to 3.92 0.0005 0.0002 2.45 1.54 to 3.94 -
Ethnicity (Caucasian vs. non-Caucasian) 1.29 0.74 to 2.25 0.3821 0.0003 2.41 1.50 to 3.87 0.87
Tumor size (> 2 cm vs. ≤ 2 cm) 1.66 1.22 to 2.26 0.0024 0.0012 2.21 1.3 to 3.57 0.67
Tumor size (> 5 cm vs. ≤ 5 cm) 2.18 1.08 to 4.37 0.0479
Grade (> 1 vs. ≤ 1) 1.12 0.35 to 3.55 0.8441 0.0011 2.22 1.38 to 3.59 0.41
Grade (> 2 vs. ≤ 2) 2.11 1.30 to 3.43 0.0015
Stage (> 1 vs. ≤ 1) 3.65 1.88 to 7.06 0.0001 0.0075 1.93 1.19 to 3.12 0.48
Stage (> 2 vs. ≤ 2) 3.59 2.19 to 5.91 < .0001
Nodal status (Pos. vs. Neg.) 2.35 1.47 to 3.77 0.0002 0.0008 2.25 1.40 to 3.60 0.50
Age (> 50 yrs vs. ≤ 50 yrs) 1.83 1.06 to 3.15 0.0204 0.0002 2.44 1.53 to 3.90 0.37
PR (Pos. vs. Neg.) 0.92 0.55 to 1.55 0.7681 0.0001 2.71 1.63 to 4.51 0.62
Adjuvant endocrine therapy (Pos. vs. Neg.) 1.28 0.78 to 2.09 0.3205 0.0002 2.42 1.51 to 3.87 0.27
Adjuvant
chemotherapy (Pos vs. Neg.)
1.24 0.81 to 1.89 0.3255 0.0003 2.40 1.49 to 3.88 0.07
Adjuvant radiotherapy (Pos. vs. Neg.) 2.40 1.49 to 3.86 0.0008 0.007 2.00 1.21 to 3.30 0.45
CPH analysis examined the impact of GP88 score and other individual clinical risk factors on OS. CI, 95% confidence interval; HR, hazard ratio. In adjusted
analysis, the successive columns provide the HR of elevated GP88 adjusted for each indicator along with its P-value and 95% CI and the interaction P-value for
the analysis of deviance test statistics for interaction between GP88 and that indicator.
Table 7 Multivariate analysis of GP88 and combined risk factors on DFS and OS
Covariate DFS OS
HR CI P HR CI P
GP88 (3+ vs. < 3+) 5.15 2.73 to 9.69 < 0.0001 1.84 1.13 to 3.00 0.0148
Ethnicity (Caucasian vs. non-Caucasian) 1.94 0.94 to 4.04 0.0744 1.03 0.57 to 1.86 0.9190
Age (> 50 yrs vs. ≤ 50 yrs) 0.66 0.34 to 1.30 0.2301 1.57 0.90 to 2.75 0.1101
Tumor size (> 2 cm vs. ≤ 2 cm) 1.06 0.50 to 2.23 0.8793 1.03 0.61 to 1.72 0.9257
Tumor size (> 5 cm vs. ≤ 5 cm) 0.44 0.09 to 2.29 0.3324 0.79 0.25 to 2.54 0.6979
Grade (> 1 vs. ≤ 1) 0.70 0.09 to 5.50 0.7309 0.54 0.16 to 1.86 0.3291
Grade (> 2 vs. ≤ 2) 0.80 0.41 to 1.57 0.5130 1.72 1.00 to 2.94 0.0501
Stage (> 1 vs. ≤ 1) 1.45 0.59 to 3.56 0.4211 2.52 1.23 to 5.14 0.0111
Stage (> 2 vs. ≤ 2) 4.21 1.78 to 9.93 0.0010 2.42 1.28 to 4.57 0.0065
Multivariate analysis determined the association of GP88 score with all other combined clinical risk factors on DFS and OS.
CI, 95% confidence interval; DFS, disease-free survival; HR, hazard ratio; OS, overall survival
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not allow us to study these prognostic and predictive
markers. In any case, the present study demonstrating
the prognostic value of GP88 expression emphasizes
that GP88 is a biologically interesting target for the
development of therapeutic and diagnostic products for
breast cancer.
Conclusion
Uncontrolled growth, survival and migration to distant
sites are hallmarks of aggressive tumors. GP88 (progra-
nulin) has been implicated in these various processes in
breast cancer cells. Here we have demonstrated that
GP88 is differentially expressed in ER+ invasive ductal
carcinoma by immunostaining and is an independent
predictor of disease-free and overall survivals beyond
five years when compared to other widely used prognos-
tic factors. These results are in agreement with the bio-
logical role of GP88 as a growth and survival factor
previously demonstrated using several breast cancer
models. These results suggest that GP88 is a target with
promising diagnostic and therapeutic potentials. Further
studies will investigate these possibilities.
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